parsaclisib

Parsaclisib is a potent, highly selective, next-generation oral small molecule inhibitor of the delta isoform of phosphoinositide 3-kinase (PI3Kδ). By inhibiting PI3Kδ, it blocks activation of the PI3K/AKT signaling pathway, leading to decreased proliferation and increased cell death in tumor cells that overexpress PI3Kδ. This isoform is primarily expressed in hematopoietic cells and is implicated in various B-cell malignancies. Parsaclisib was developed for use in relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and other B-cell lymphomas. It was designed to improve tolerability compared to earlier PI3K inhibitors by reducing off-target toxicities such as hepatotoxicity[1][2][4][5][6][7][8].

Other names

1426698-88-5parsaclisib [INN]parsaclisib [USAN]